CI Global Health Sciences Corporate Class

Series P USD
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date May 2017
CAD Total net assets ($CAD)
As at 2025-05-30
$143.1 million
NAVPS
As at 2025-06-27
$8.3410
MER (%)
As at 2024-09-30
0.24
Management fee (%) 0.90
Asset class Sector Equity
Currency USD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.1669

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

P 90324
A ISC 301
DSC SO* 401
LL SO 1401
F 324
*No new purchases directly into switch only funds.

Performance2 As at 2025-05-31

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
-6.70% -6.51% -12.66% -13.75% -16.21% -0.88% 1.48% - 3.39%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.1669
2021-03-26 0.0563
2020-12-18 0.0892
2020-09-25 0.0844
2020-06-26 0.0615
Payable date Total
2020-03-20 0.1428
2019-12-13 0.0890
2019-09-27 0.0991
2019-06-21 0.0930
2019-03-22 0.1458

Management team

First we'll display the Team Company and then the Team members
Greg Quickmire
Peter Hofstra

CI Global Health Sciences Corporate Class

Series P USD
 
Portfolio allocations4 As at 2025-05-31
Asset allocation (%)
  • US Equity 83.15
  • International Equity 15.49
  • Cash and Equivalents 1.35
  • Other 0.01
Sector allocation (%)
  • Healthcare 98.56
  • Cash and Cash Equivalent 1.35
  • Other 0.09
Geographic allocation(%)
  • United States 83.92
  • United Kingdom 8.07
  • Switzerland 3.10
  • Germany 2.19
  • Denmark 2.13
  • Canada 0.50
  • Other 0.09
Top holdings5
Sector (%)
1. Eli Lilly and Co Drugs 10.55%
2. AbbVie Inc Drugs 8.97%
3. Thermo Fisher Scientific Inc Healthcare Equipment 8.35%
4. AstraZeneca PLC Drugs 8.07%
5. Merck & Co Inc Drugs 7.85%
6. UnitedHealth Group Inc Healthcare Services 7.83%
7. DexCom Inc Healthcare Equipment 5.32%
8. Intuitive Surgical Inc Healthcare Equipment 4.74%
9. Stryker Corp Healthcare Equipment 4.57%
10. Gilead Sciences Inc Drugs 4.50%
11. Boston Scientific Corp Healthcare Equipment 4.25%
12. Danaher Corp Healthcare Equipment 4.07%
13. Anthem Inc Healthcare Services 3.98%
14. Lonza Group AG Drugs 3.10%
15. IQVIA Holdings Inc Drugs 3.02%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.